CN110172427A - 一种提高狄氏副拟杆菌冻干存活率的方法及应用 - Google Patents
一种提高狄氏副拟杆菌冻干存活率的方法及应用 Download PDFInfo
- Publication number
- CN110172427A CN110172427A CN201910500753.1A CN201910500753A CN110172427A CN 110172427 A CN110172427 A CN 110172427A CN 201910500753 A CN201910500753 A CN 201910500753A CN 110172427 A CN110172427 A CN 110172427A
- Authority
- CN
- China
- Prior art keywords
- freeze
- drying
- parabacteroides
- distirii
- protective agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004108 freeze drying Methods 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims abstract description 33
- 230000004083 survival effect Effects 0.000 title claims abstract description 18
- 241000606125 Bacteroides Species 0.000 title abstract 7
- 241000160321 Parabacteroides Species 0.000 claims abstract description 30
- 229930006000 Sucrose Natural products 0.000 claims abstract description 28
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 28
- 239000005720 sucrose Substances 0.000 claims abstract description 28
- 239000003223 protective agent Substances 0.000 claims abstract description 27
- 230000001580 bacterial effect Effects 0.000 claims abstract description 26
- 241000894006 Bacteria Species 0.000 claims abstract description 25
- 239000000843 powder Substances 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 17
- 239000000725 suspension Substances 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000006041 probiotic Substances 0.000 claims description 9
- 235000018291 probiotics Nutrition 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 6
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 239000010802 sludge Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000002054 inoculum Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 230000030833 cell death Effects 0.000 abstract 1
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 235000020183 skimmed milk Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000009777 vacuum freeze-drying Methods 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010053481 Antifreeze Proteins Proteins 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- -1 MgSO 4 Chemical compound 0.000 description 1
- 241000606210 Parabacteroides distasonis Species 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 125000003716 cholic acid group Chemical group 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种提高狄氏副拟杆菌冻干存活率的方法及其应用,属于微生物工程技术领域。本发明为一种通过添加蔗糖溶液从而减少拟杆菌在冷冻干燥过程中的细胞死亡的方法。主要包括蔗糖的添加和拟杆菌的冷冻干燥。通过整套方法,可以在3‑5天内快速的得到拟杆菌冻干菌粉。蔗糖作为冷冻干燥保护剂的添加,有效提高了拟杆菌在冷冻干燥过程的存活率,减少了拟杆菌冻干过程中的死亡率,增加拟杆菌制剂在其之后的使用过程中的适用能力及活性。此外,由于蔗糖对人畜安全无害,这一思路可以用于直接食用冻干菌粉的制作过程。
Description
技术领域
本发明涉及一种提高狄氏副拟杆菌冻干存活率的方法,属于微生物工程技术领域。
背景技术
狄氏副拟杆菌(Parabacteroides distasonis)具有广泛的胆酸转化功能,能够改善脂代谢紊乱、修复肠壁完整性、激活肠道糖异生,从而调节食欲,促进肝脏糖原合成,改善宿主糖代谢紊乱。其主要是通过产生琥珀酸、次级胆酸来激活不同的信号通路,发挥多靶点整体调节作用,是一种潜在的、新型抗代谢综合征益生菌。以狄氏副拟杆菌为代表的下一代益生菌的产品开发、加工和利用将成为一个新的研究热点。在市场上,益生菌产品主要以两种形式销售:食品和膳食补充剂。其中还有益生菌的食品几乎都是奶制品。而含益生菌的膳食补充剂产品品种较多,剂型有胶囊、粉剂、口服液、片剂等。
真空冻干是目前菌粉生产中的常用工艺流程。培养得到的活菌经过离心得到菌泥,重悬后低温冷冻,在真空条件下,低温使冰直接升华,实现冷冻干燥。在此过程中,菌体受到低温胁迫、冻结应力损伤等,导致细胞膜通透性改变、蛋白质变性失活、pH的动态平衡被破坏等。因此真空冻干对微生物活性有较大的影响,在真空冻干前,需要加入特定的冻干保护剂。
常用的冻干保护剂包括甘油、蔗糖、海藻糖、脱脂乳粉、谷氨酸钠等。不同菌株由于生理特性及菌体表面特性差异,所用的保护剂不尽相同,故而大部分菌体保护剂具有专一性,无法直接应用于其他菌株的冻干技术中。比如,在ChIFN酿酒酵母工程菌冻干保护剂的优化实验中,用半乳糖、乳糖、蔗糖、葡萄糖、海藻糖、山梨醇、甘露醇、聚乙二醇、半胱氨酸盐、β-环状糊精和脱脂奶粉进行单一和复配实验,单一保护剂对细胞存活率的影响结果表明,脱脂奶粉、蔗糖、海藻糖、乳糖、甘油、聚乙二醇对工程菌的保护效率分别为43.73%、37.78%、30.60%、29.25%、28.94%、28.45%;而获得的蔗糖(144.4g/L)+脱脂奶粉(100.8g/L)+聚乙二醇(11.1g/L)配比的复合保护剂对工程菌保护作用达到最大,保护效率为80.81%(见文献:张冬生,刘宗,宋莉,et al.ChIFN酿酒酵母工程菌冻干保护剂的优化[J].山地农业生物学报,2018,37(1):90-94.)。
蔗糖为小分子膜外保护剂,适当浓度的蔗糖可以降低膜外溶液的电解质浓度,减少阳离子进入细胞的数量,缓解胞内结冰情况。蔗糖在干燥中抑制了细胞膜的相变,即在冻干脱水时,由于蔗糖具有水置换作用,蔗糖分子羟基与磷脂上磷酸基团连接形成氢键,从而阻止和限制细胞膜因脱水造成融合,并降低相变温度,使脂膜不向凝胶相转变而保持液晶相,增加膜流动性,使干燥脂膜与水合质膜生理特性相同。
目前市场上没有用于狄氏副拟杆菌的冷冻干燥保护剂,狄氏副拟杆菌的冻干保护剂是一项尚待开发的工作。
发明内容
本发明的第一个目的是提供一种狄氏副拟杆菌冻干粉的制备方法,所述方法包括:
(1)狄氏副拟杆菌的前处理,(2)冷冻干燥的预处理,(3)冷冻干燥;所述步骤(1)具体为:
a)将狄氏副拟杆菌单菌落接种到BHI培养液中培养;
b)将步骤a)所得培养液离心去上清液后,洗涤所获得的菌泥;
c)重悬洗涤后的菌体,获得菌悬液;
所述步骤(2)是在步骤c)的菌悬液中添加质量体积浓度为10-30%的蔗糖溶液作为保护剂,转移至冻干瓶;
(3)冷冻干燥。
在本发明的一种实施方式中,将菌悬液与蔗糖溶液混合,菌悬液与保护剂的体积比为1:2-2:1,菌悬液中含3×1010-5×1010CFU/mL狄氏副拟杆菌细胞。
在本发明的一种实施方式中,步骤(a)所述培养条件为:35-38℃静置培养10-30h。
在本发明的一种实施方式中,步骤(a)所述培养包括:以1-5%的接种量将狄氏副拟杆菌进行第一次扩培,扩培体积为100mL,培养条件为35-38℃、10-15h。
在本发明的一种实施方式中,步骤(a)所述培养包括:以1-5%的接种量将狄氏副拟杆菌进行第二次扩培,扩培体积为1L,培养条件为35-38℃、10-15h。
在本发明的一种实施方式中,步骤(a)中狄氏副拟杆菌的接种量为1-5%(V/V)。
在本发明的一种实施方式中,冷冻干燥条件为:在-55~-45℃下预冻3-5h,在-35~-25℃一次干燥17-19h,再升温到20~30℃,13-15h之后取出冻干瓶密封,得到干燥的菌粉。
在本发明的一种实施方式中,步骤(b)所述洗涤是用生理盐水洗涤两次,步骤(c)所述重悬是用生理盐水重悬。
在本发明的一种实施方式中,步骤(c)中将菌泥与生理盐水按照1:1(g/mL)的比例混合。
在本发明的一种实施方式中,所述狄氏副拟杆菌包括狄氏副拟杆菌ATCC 8503或狄氏副拟杆菌ATCC BAA-1295。
本发明的第二个目的是提供一种提高狄氏副拟杆菌冻干存活率的方法,是利用质量体积浓度为10-30%的蔗糖溶液作为冻干保护剂,将菌悬液与保护剂按体积比为1:2-2:1混合,菌悬液中含3×1010-5×1010CFU/mL狄氏副拟杆菌细胞。
本发明的第三个目的是提供上述方法在制备益生菌产品中的应用。
本发明的第四个目的是提供上述方法制备的益生菌产品。
本发明的有益效果:
本发明提供了一种提高狄氏副拟杆菌冻干存活率的方法,以增强拟杆菌制剂在后续使用过程中的应用效能。主要包括蔗糖的添加和狄氏副拟杆菌的冷冻干燥。通过整套方法,可以在3-5天内快速得到狄氏副拟杆菌冻干菌粉。添加蔗糖溶液作为冷冻干燥保护剂,狄氏副拟杆菌在冷冻干燥过程的存活率达到13.89%,减少了菌株冻干过程中的死亡率,增加狄氏副拟杆菌制剂在其之后的使用过程中的适用能力及活性。此外,由于蔗糖对人畜安全无害,这一思路可以用于直接食用冻干菌粉的制作过程。
附图说明
图1:菌株添加保护剂后的冻干存活率。
具体实施方式
相关培养基及试剂:
BHI液体培养基:38.5g/L脑心浸液培养基,1g/L半胱氨酸盐酸盐,1mL/L维生素K,10mL/L血晶质,调节PH至7.0,115℃灭菌20分钟;
BHI固体培养基:38.5g/L脑心浸液培养基,1g/L半胱氨酸盐酸盐,1mL/L维生素K,10mL/L血晶质,15g/L琼脂粉,调节PH至7.0,115℃灭菌20分钟;
血晶质溶液(1mg/mL):0.28gKOH、25.0mL无水乙醇、100mg血晶质固体,加水至100mL,保存于4℃;
维生素K1溶液(2mg/mL):140mg维生素K、20mL无水乙醇,保存于4℃。
实施例1单因素冻干保护剂的筛选
(1)配置10种保护剂:甘油、MgSO4、NaCl、乳糖、海藻糖、蔗糖、乳清蛋白、脱脂乳粉、甘露醇、山梨醇,保护剂配制成质量浓度为20%的水溶液,调节pH至7.0,115℃灭菌20分钟。其中两种蛋白质类保护剂(乳清蛋白及脱脂乳粉)采用巴氏杀菌方式,即:75℃,20min。
(2)保护剂的添加:将10g菌泥与10mL生理盐水混匀,涡旋震荡充分混匀,调pH至7.0,各取2mL菌悬液分装到含1mL各种保护剂溶液的5mL EP管里,共3mL,继续涡旋震荡充分混匀。
(3)冻干前活菌计数:采用菌落平板计数法,即在无菌操作条件下,取0.5mL步骤(2)中的混液加入到分装了4.5mL生理盐水的EP管中,制成1:10的均匀稀释液,再依次进行10倍梯度稀释,至适当稀释度10-7、10-8、10-9后,分别取各稀释浓度1mL于固体培养皿中,与已融化并冷却至45℃左右的BHI固体培养基约15mL混合,使菌体分散均匀,待凝固后倒置,放入厌氧培养箱中培养14h,记录每个平皿中形成的菌落数量,依据稀释倍数,计算出每毫升原始样品中所含细菌菌落总数,来表示活菌数。每个稀释度做4个平行。
(4)冷冻干燥:取1mL步骤(2)中含保护剂的菌液分别加入每个冻干瓶中。每个保护剂做两个平行。经过-40℃预冻30min,在-25℃升华30h,再阶梯式升温到30℃,共20h,得到干燥的菌粉。
(5)细菌复水及活菌计数:将冷冻干燥后的样品加入1mL生理盐水复水,涡旋震荡充分混匀,采用菌落平板计数法,即在无菌操作条件下,取0.5mL复水后的菌液加入到分装了4.5mL生理盐水的EP管中,制成1:10的均匀稀释液,再依次进行10倍梯度稀释,至适当稀释度10-8、10-9后,分别取各稀释浓度1mL于固体培养皿中,与已融化并冷却至45℃左右的BHI固体培养基约15mL混合,使菌体分散均匀,待凝固后倒置,放入厌氧培养箱中培养14h,记录每个平皿中形成的菌落数量,依据稀释倍数,计算出每毫升原始样品中所含细菌菌落总数,来表示活菌数。每个稀释度做4个平行。
表1.菌株添加保护剂后冻干存活率
注:表1中0.00%的结果是代表存活率小于0.0092%
实验结果如图1和表1所示。蔗糖作为一种冻干效果较佳的保护剂,存活率达到了13.89%。与此相比,空白对照组的存活率仅有0.0083%,不到0.01%,说明这株菌抗冻抗干燥能力较弱。对乳酸菌冻干保护效果较好的蛋白质类保护剂脱脂乳粉的存活率仅为0.09%,蔗糖与其保护效果相比提高了13.8%的存活率。与同类保护剂相比,添加蔗糖后菌株的存活率也明显高于乳糖与海藻糖,分别提高了6.3%、13.01%。说明本发明保护剂对于冻干狄氏副拟杆菌菌株的保护作用具有明显的优势。
对比例1
添加质量体积浓度为40%的蔗糖溶液作为保护剂,其余条件同实施例1,菌株的冻干存活率为7.06%。
对比例2
添加菌悬液和蔗糖溶液的体积比为3:1,其余条件同实施例1,菌株的冻干存活率为8.11%。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (10)
1.一种狄氏副拟杆菌冻干粉的制备方法,其特征在于,所述方法包括:
(1)狄氏副拟杆菌的前处理,(2)冷冻干燥的预处理,(3)冷冻干燥;所述步骤(1)具体为:
a)将狄氏副拟杆菌单菌落接种到BHI培养液中培养;
b)将步骤a)所得培养液离心去上清液后,洗涤所获得的菌泥;
c)重悬洗涤后的菌体,获得菌悬液;
所述步骤(2)是在步骤c)的菌悬液中添加质量体积浓度为10-30%的蔗糖溶液作为保护剂,转移至冻干瓶;
(3)冷冻干燥。
2.如权利要求1所述的方法,其特征在于,将菌悬液与蔗糖溶液混合,菌悬液与保护剂的体积比为1:2-2:1,菌悬液中含3×1010-5×1010CFU/mL狄氏副拟杆菌细胞。
3.如权利要求1所述的方法,其特征在于,步骤(a)所述培养条件为:35-38℃静置培养10-30h。
4.如权利要求1~3任一所述的方法,其特征在于,步骤(a)中狄氏副拟杆菌的接种量为1-5%(V/V)。
5.如权利要求1所述的方法,其特征在于,冷冻干燥条件为:在-55~-45℃下预冻3-5h,在-35~-25℃一次干燥17-19h,再升温到20~30℃,13-15h之后取出冻干瓶密封,得到干燥的菌粉。
6.如权利要求1所述的方法,其特征在于,步骤(b)所述洗涤是用生理盐水洗涤两次,步骤(c)所述重悬是用生理盐水重悬。
7.如权利要求1所述的方法,其特征在于,步骤(c)中将菌泥与生理盐水按照1:1(g/mL)的比例混合。
8.一种提高狄氏副拟杆菌冻干存活率的方法,其特征在于,是利用质量体积浓度为10-30%的蔗糖溶液作为冻干保护剂,将菌悬液与保护剂按体积比为1:2-2:1混合,菌悬液中含3×1010-5×1010CFU/mL狄氏副拟杆菌细胞。
9.权利要求1-8任一所述方法在制备益生菌产品中的应用。
10.权利要求1~7任一所述方法制备的益生菌产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910500753.1A CN110172427A (zh) | 2019-06-11 | 2019-06-11 | 一种提高狄氏副拟杆菌冻干存活率的方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910500753.1A CN110172427A (zh) | 2019-06-11 | 2019-06-11 | 一种提高狄氏副拟杆菌冻干存活率的方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110172427A true CN110172427A (zh) | 2019-08-27 |
Family
ID=67698211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910500753.1A Pending CN110172427A (zh) | 2019-06-11 | 2019-06-11 | 一种提高狄氏副拟杆菌冻干存活率的方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110172427A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112322545A (zh) * | 2020-11-19 | 2021-02-05 | 山东龙昌动物保健品有限公司 | 一株狄氏副拟杆菌lcg-06及其与胆汁酸复配的复合菌剂与应用 |
CN112401083A (zh) * | 2020-11-19 | 2021-02-26 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂及其在用于制备蛋鸡饲料添加剂中的应用 |
CN112401077A (zh) * | 2020-11-19 | 2021-02-26 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂在用于制备猪饲料添加剂中的应用 |
CN112401071A (zh) * | 2020-11-19 | 2021-02-26 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂在用于制备肉羊饲料添加剂中的应用 |
CN112425681A (zh) * | 2020-11-19 | 2021-03-02 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂在用于制备黄颡鱼饲料添加剂中的应用 |
CN113143971A (zh) * | 2021-02-03 | 2021-07-23 | 山东龙昌动物保健品有限公司 | 胆汁酸复合菌剂在用于制备防治宠物泪痕的制剂中的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108430483A (zh) * | 2015-11-03 | 2018-08-21 | 布里格姆及妇女医院股份有限公司 | 用于治疗和/或预防食物变态反应的治疗性微生物群 |
US20180296582A1 (en) * | 2015-04-23 | 2018-10-18 | Kaleido Biosciences, Inc. | Microbiome regulators and related uses thereof |
CN108738311A (zh) * | 2015-06-15 | 2018-11-02 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
-
2019
- 2019-06-11 CN CN201910500753.1A patent/CN110172427A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180296582A1 (en) * | 2015-04-23 | 2018-10-18 | Kaleido Biosciences, Inc. | Microbiome regulators and related uses thereof |
CN108738311A (zh) * | 2015-06-15 | 2018-11-02 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
CN108430483A (zh) * | 2015-11-03 | 2018-08-21 | 布里格姆及妇女医院股份有限公司 | 用于治疗和/或预防食物变态反应的治疗性微生物群 |
Non-Patent Citations (2)
Title |
---|
SAMUEL B. LESLIE等: "Trehalose and Sucrose Protect Both Membranes and Proteins in Intact Bacteria during Drying", 《APPLIED AND ENVIRONMENTAL MICROBIOLOGY》 * |
朱敖兰等: "生物制品冻干保护剂及其保护机理的研究进展", 《喀什师范学院学报》 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112322545A (zh) * | 2020-11-19 | 2021-02-05 | 山东龙昌动物保健品有限公司 | 一株狄氏副拟杆菌lcg-06及其与胆汁酸复配的复合菌剂与应用 |
CN112401083A (zh) * | 2020-11-19 | 2021-02-26 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂及其在用于制备蛋鸡饲料添加剂中的应用 |
CN112401077A (zh) * | 2020-11-19 | 2021-02-26 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂在用于制备猪饲料添加剂中的应用 |
CN112401071A (zh) * | 2020-11-19 | 2021-02-26 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂在用于制备肉羊饲料添加剂中的应用 |
CN112425681A (zh) * | 2020-11-19 | 2021-03-02 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂在用于制备黄颡鱼饲料添加剂中的应用 |
CN112401071B (zh) * | 2020-11-19 | 2021-08-27 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂在用于制备肉羊饲料添加剂中的应用 |
CN112401077B (zh) * | 2020-11-19 | 2022-11-18 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂在用于制备猪饲料添加剂中的应用 |
CN112425681B (zh) * | 2020-11-19 | 2023-03-24 | 山东龙昌动物保健品有限公司 | 一种胆汁酸复合菌剂在用于制备黄颡鱼饲料添加剂中的应用 |
CN113143971A (zh) * | 2021-02-03 | 2021-07-23 | 山东龙昌动物保健品有限公司 | 胆汁酸复合菌剂在用于制备防治宠物泪痕的制剂中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110172427A (zh) | 一种提高狄氏副拟杆菌冻干存活率的方法及应用 | |
Torp et al. | Optimizing oral delivery of next generation probiotics | |
CA2917109C (en) | A method of freeze-drying encapsulated cells, freeze-dried encapsulated cells, compositions containning freeze-dried encapsulated cells and uses of such cells and compositions | |
CN103932186B (zh) | 一种长双歧杆菌微胶囊及其制备方法 | |
EP2649175B1 (en) | Starter culture compositions | |
Wang et al. | Polysaccharides can improve the survival of Lactiplantibacillus plantarum subjected to freeze-drying | |
Alonso | Novel preservation techniques for microbial cultures | |
Jofré et al. | Impact of different cryoprotectants on the survival of freeze-dried Lactobacillus rhamnosus and Lactobacillus casei/paracasei during long-term storage | |
CN107287121A (zh) | 一种乳酸菌冻干保护剂及其制备方法和使用方法 | |
Hongpattarakere et al. | Improvement of freeze-dried Lactobacillus plantarum survival using water extracts and crude fibers from food crops | |
CN110607255B (zh) | 一种德氏乳杆菌及直投式德氏乳杆菌发酵剂的制备方法和应用 | |
CN102952755A (zh) | 一种保加利亚乳杆菌冻干保护剂及其制备方法 | |
CN106047709A (zh) | 一种植物乳杆菌冻干粉及其制备方法 | |
Béal et al. | Freezing of probiotic bacteria | |
Chen et al. | Lactic acid bacteria starter | |
Ge et al. | Optimization of cryoprotectants for improving the freeze-dried survival rate of potential probiotic Lactococcus lactis ZFM559 and evaluation of its storage stability | |
Pandey et al. | Encapsulation of probiotic bacillus coagulans for enhanced shelf life | |
CN111534434B (zh) | 一种冻干保护剂及其在冻干青春双歧杆菌中的应用 | |
CN108546647A (zh) | 一种双歧杆菌冻干制剂及其专用保护剂 | |
CN112795558A (zh) | 一种提升乳酸菌稳定性的三层包埋方法 | |
Mutukumira et al. | Microencapsulation of probiotic bacteria | |
CN103893776B (zh) | 羊传染性脓疱病毒细胞弱毒疫苗耐热冻干保护剂及其制备方法和应用 | |
RU2425576C1 (ru) | Сухой пробиотически активный биопрепарат и способ получения кисломолочного напитка на его основе | |
Urbański et al. | Influence of whey on viability of Lactobacillus gasseri during freeze-drying process | |
CN108085256A (zh) | 一种冻干保护剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190827 |